251 related articles for article (PubMed ID: 23911412)
1. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
[TBL] [Abstract][Full Text] [Related]
2. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
[TBL] [Abstract][Full Text] [Related]
3. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
[TBL] [Abstract][Full Text] [Related]
4. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
Sier CF; Gelderman KA; Prins FA; Gorter A
Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
[TBL] [Abstract][Full Text] [Related]
5. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
6. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
[TBL] [Abstract][Full Text] [Related]
7. Modified human beta 2-microglobulin (desLys(58)) displays decreased affinity for the heavy chain of MHC class I and induces nitric oxide production and apoptosis.
Wang M; Harhaji L; Lamberth K; Harndahl M; Buus S; Heegaard NH; Claesson MH; Nissen MH
Scand J Immunol; 2009 Mar; 69(3):203-12. PubMed ID: 19281532
[TBL] [Abstract][Full Text] [Related]
8. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; de Jong RN; Beurskens FJ; Schuurman J; Parren PW; Taylor RP
Mol Immunol; 2016 Feb; 70():13-23. PubMed ID: 26690706
[TBL] [Abstract][Full Text] [Related]
9. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.
Livingston PO; Hood C; Krug LM; Warren N; Kris MG; Brezicka T; Ragupathi G
Cancer Immunol Immunother; 2005 Oct; 54(10):1018-25. PubMed ID: 15926079
[TBL] [Abstract][Full Text] [Related]
10. Human leukocyte antigen antibodies and human complement activation: role of IgG subclass, specificity, and cytotoxic potential.
Kushihata F; Watanabe J; Mulder A; Claas F; Scornik JC
Transplantation; 2004 Oct; 78(7):995-1001. PubMed ID: 15480164
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
12. Covalent binding of C3b to monoclonal antibodies selectively up-regulates heavy chain epitope recognition by T cells.
Santoro L; Drouet C; Reboul A; Mach JP; Colomb MG
Eur J Immunol; 1994 Jul; 24(7):1620-6. PubMed ID: 8026522
[TBL] [Abstract][Full Text] [Related]
13. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
14. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement.
Rosales C; Jeglum KA; Obrocka M; Steplewski Z
Cell Immunol; 1988 Sep; 115(2):420-8. PubMed ID: 3409330
[TBL] [Abstract][Full Text] [Related]
15. The 4H84 monoclonal antibody detecting beta2m free nonclassical HLA-G molecules also binds to free heavy chains of classical HLA class I antigens present on activated lymphocytes.
Poláková K; Kuba D; Russ G
Hum Immunol; 2004 Feb; 65(2):157-62. PubMed ID: 14969770
[TBL] [Abstract][Full Text] [Related]
16. Cellular expression or binding of desLys58-beta2 microglobulin is not dependent on the presence of the tri-molecular MHC class I complex.
Wang M; Corlin DB; Heegaard NH; Claesson MH; Nissen MH
Scand J Immunol; 2008 Feb; 67(2):105-12. PubMed ID: 18069937
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
Tammen A; Derer S; Schwanbeck R; Rösner T; Kretschmer A; Beurskens FJ; Schuurman J; Parren PW; Valerius T
J Immunol; 2017 Feb; 198(4):1585-1594. PubMed ID: 28062698
[TBL] [Abstract][Full Text] [Related]
18. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.
Beum PV; Kennedy AD; Li Y; Pawluczkowycz AW; Williams ME; Taylor RP
J Immunol Methods; 2004 Nov; 294(1-2):37-42. PubMed ID: 15604014
[TBL] [Abstract][Full Text] [Related]
19. Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.
Awwad M; Strome PG; Gilman SC; Axelrod HR
Cancer Immunol Immunother; 1994 Jan; 38(1):23-30. PubMed ID: 8299115
[TBL] [Abstract][Full Text] [Related]
20. Gastric cancer progression may involve a shift in HLA-E profile from an intact heterodimer to β2-microglobulin-free monomer.
Sasaki T; Ravindranath MH; Terasaki PI; Freitas MC; Kawakita S; Jucaud V
Int J Cancer; 2014 Apr; 134(7):1558-70. PubMed ID: 24105714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
